M
Martin Hutchings
Researcher at Copenhagen University Hospital
Publications - 215
Citations - 9374
Martin Hutchings is an academic researcher from Copenhagen University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 36, co-authored 159 publications receiving 7464 citations. Previous affiliations of Martin Hutchings include Nagoya University & St Thomas' Hospital.
Papers
More filters
Journal ArticleDOI
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington,N. George Mikhaeel,Lale Kostakoglu,Michel Meignan,Martin Hutchings,Stefan P. Müeller,Lawrence H. Schwartz,Emanuele Zucca,Richard I. Fisher,Judith Trotman,Otto S. Hoekstra,Rodney J. Hicks,Michael O'Doherty,Roland Hustinx,Alberto Biggi,Bruce D. Cheson +15 more
TL;DR: This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Journal ArticleDOI
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
Andrea Gallamini,Martin Hutchings,Luigi Rigacci,Lena Specht,Francesco Merli,Mads Hansen,Caterina Patti,Annika Loft,Francesco Di Raimondo,Francesco d'Amore,Alberto Biggi,Umberto Vitolo,Caterina Stelitano,R Sancetta,Livio Trentin,Stefano Luminari,Emilio Iannitto,Simonetta Viviani,Ivana Pierri,Alessandro Levis +19 more
TL;DR: PET-2 overshadows the prognostic value of IPS and emerges as the single most important tool for planning of risk-adapted treatment in advanced HL.
Journal ArticleDOI
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
Martin Hutchings,Annika Loft,Annika Loft,Mads Hansen,Mads Hansen,Lars Møller Pedersen,Lars Møller Pedersen,Thora Buhl,Thora Buhl,Jesper Jurlander,Jesper Jurlander,Simon Buus,Simon Buus,Susanne Keiding,Susanne Keiding,Francesco d'Amore,Francesco d'Amore,Anne-Marie Boesen,Anne-Marie Boesen,Anne Kiil Berthelsen,Anne Kiil Berthelsen,Lena Specht,Lena Specht +22 more
TL;DR: For prediction of PFS, interim FDG-PET was as accurate after two cycles as later during treatment and superior to computerized tomography (CT) at all times and in regression analyses, early interimFDG- PET was stronger than established prognostic factors.
Journal ArticleDOI
FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma
TL;DR: An early assessment of chemotherapy response with FDG-PET could provide the basis for selection of patients for alternative therapeutic strategies and be an accurate and independent predictor of PFS and OS.
Journal ArticleDOI
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Dennis A. Eichenauer,Andreas Engert,Marc André,Massimo Federico,Timothy M Illidge,Martin Hutchings,Marco Ladetto +6 more
TL;DR: The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in mortality and morbidity and to help clarify the role of immune checkpoints in this disease.